跳转至内容
Merck

PHR1422

Supelco

阿托伐他汀钙

Pharmaceutical Secondary Standard; Certified Reference Material

别名:

阿托伐他汀钙 CRM 半钙盐 倍半水合物, 1H-吡咯-1-庚酸, [R-(R*,R*)]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲乙基)-3-苯基-4-[(苯氨基)羰基], 钙盐(2:1)

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C66H68CaF2N4O10 · 3H2O
分子量:
1209.39
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material
pharmaceutical secondary standard

品質等級

agency

traceable to Ph. Eur. Y0001327
traceable to USP 1044516

API 家族

atorvastatin

CofA

current certificate can be downloaded

技術

HPLC: suitable
gas chromatography (GC): suitable

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-30°C

InChI

1S/2C33H35FN2O5.Ca.3H2O/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;;;;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);;3*1H2/q;;+2;;;/p-2/t2*26-,27-;;;;/m11..../s1

InChI 密鑰

SHZPNDRIDUBNMH-NIJVSVLQSA-L

正在寻找类似产品? 访问 产品对比指南

一般說明

阿托伐他汀钙是合成的降胆固醇制剂, 可作为抑制剂,抑制3-羟基-3-甲基戊二酰辅酶A还原酶。 普遍与苯磺酸氨氯地平联合使用,作为药物治疗血管痉挛性心绞痛、高血压、慢性稳定型心绞痛和原发性脂蛋白异常血症。
用于质量控制的药品二级标准品,为制药实验室和制造商提供了一种方便且经济的替代方案,可用于内部工作标准品的制备。

應用

硫唑嘌呤可用作药物参考标准品,通过反相高效液相色法(RP-HPLC) 和分光光度技术,定量药物制剂中 的分析物。
这些二级标准品是经过检验的认证标准物质(CRM)。它们适用于多种分析应用,包括但不限于药物释放测试、药物的定性和定量分析方法开发、食品和饮料质量控制检测以及其他标定应用。

分析報告

这些二级标准品可多次溯源至美国药典、欧洲药典和英国药典一级标准品(如可用)。

其他說明

该认证标准物质(CRM)根据ISO 17034ISO/IEC 17025进行生产和认证。有关此CRM使用的所有信息均可在分析证书上找到。

腳註

要查看该材料的检验报告示例,在下面的栏位中输入 LRAC0148。这只是一个示例证书,可能不是您收到的批次。

分析物

说明

    Atorvastatin hemicalcium salt sesquihydrate

相關產品

产品编号
说明
价格

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Carc. 2 - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Simultaneous Spectrophotometric Determination of Atorvastatin Calcium and Ezetimibe in Tablet Dosage Form
GRB, et al.
International Journal of ChemTech Research, 1(2), 233-236 (2009)
Risheng Yang et al.
Oncogene, 39(40), 6340-6353 (2020-08-29)
Isocitrate dehydrogenase (IDH) mutation is the most important initiating event in gliomagenesis, and the increasing evidence shows that IDH mutation is associated with the metabolic reprogramming in the tumor. Dysregulated cholesterol metabolism is a hallmark of tumor cells, but the
Yanli Wang et al.
Histology and histopathology, 29(12), 1593-1600 (2014-08-01)
Statins are often prescribed for treatment of cardiovascular diseases, although there are still many patients who cannot be effectively treated by statins alone. Both probucol and cilostazol exhibit anti-atherogenic effects. In the current study, we attempted to investigate whether a
Shen Li et al.
Journal of atherosclerosis and thrombosis, 21(7), 648-658 (2014-03-04)
Probucol is a lipid-lowering drug that is often prescribed for the treatment of familial hypercholesterolemia. However, it is not known whether probucol can change the lesion quality of atherosclerosis. We examined this possibility using WHHL rabbits, a model of human
Yuka Keyamura et al.
PloS one, 9(5), e96929-e96929 (2014-05-09)
Lowering the blood concentration of low-density lipoprotein (LDL) cholesterol is the primary strategy employed in treating atherosclerotic disorders; however, most commonly prescribed statins prevent cardiovascular events in just 30% to 40% of treated patients. Therefore, additional treatment is required for

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门